IVD Medical (1931) H1 2025 earnings summary

Executive summary

• Revenue for the six months ended 30 June 2025 was RMB1,269.6 million, down 6.2% year-over-year due to decreased market demand.

• Net profit fell 70.0% to RMB38.3 million, mainly from lower revenue, reduced gross margin, higher labor, administrative, and selling costs.

• Adjusted profit (non-GAAP) dropped 72.1% to RMB35.6 million, reflecting core operational performance.

• No interim dividend declared for the period.

• The Group remains a leading distributor of IVD products in China, with a broad network and strong hospital coverage.

Financial highlights

• Gross profit decreased 13.9% to RMB279.6 million; gross margin fell to 22.0% from 24.0%.

• EBITDA declined 46.3% to RMB113.8 million.

• Net profit margin dropped to 3.0% from 9.4% year-over-year; return on equity fell to 1.1% from 3.7%.

• Cash and cash equivalents at period end were RMB424.8 million, down 76.1% from year-end 2024.

• Gearing ratio increased to 26.9% from 13.3% at year-end 2024.

Outlook and guidance

• Plans to expand product portfolio, distribution network, and hospital coverage to capture IVD market growth.

• Strategic focus on technological innovation, including AI, robotics, and digital asset integration.

• Entered global strategic cooperation with HashKey Group to establish an Ethereum vault and explore tokenization of medical R&D assets.

• Intends to enhance solution services with data-driven models and automated tools.